A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.

Abstract

BACKGROUND Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. However, the activity of gefitinib as first-line chemotherapy remains unclear, especially unknown in elderly patients. A multicenter phase II trial was conducted to evaluate the efficacy and tolerability of gefitinib for elderly patients with chemotherapy-naïve NSCLC. METHODS Elderly chemotherapy-naïve patients with advanced NSCLC, ECOG PS of 0-2, and adequate organ functions received 250 mg/day of gefitinib. The primary objective of this study was to determine the objective response rate (RR). Secondary endpoints were tolerability, disease-related symptom using lung cancer subscale (LCS) in FACT-L, progression free survival (PFS) and overall survival (OS). We investigated mutation status of the epidermal growth factor receptor (EGFR) gene in cases with available tumor samples. RESULTS Fifty patients were enrolled, of whom 49 were eligible. Median age (range) was 80 (75-90) years. Thirty-two patients were female (65%) and 40 patients had adenocarcinoma (82%). The objective RR was 25% (CI 95%, 13-39). Median survival time was 10 months (CI 95%, 7-20) and 1-year survival rate was 50%. The most frequent adverse events were skin disorders (76%). Fifteen patients (30%) experienced toxicities >/=grade 3. There were four patients with possible interstitial lung disease including two treatment-related deaths. Symptom improvement rate using LCS was 49% at 4 weeks of gefitinib therapy. Tumor samples from 17 patients were analyzed for EGFR mutation status. EGFR mutations were detected in tumor tissues from 7 patients, of which 5 had partial responses (71%). CONCLUSIONS Gefitinib monotherapy is effective and relatively well tolerated in chemotherapy-naïve elderly patients with advanced NSCLC. Gefitinib has potential as a first-line therapeutic option in elderly patients with advanced NSCLC.

DOI: 10.1097/JTO.0b013e318186a88d

Statistics

0100200300'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

533 Citations

Semantic Scholar estimates that this publication has 533 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ebi2008API, title={A phase II trial of gefitinib monotherapy in chemotherapy-na{\"{i}ve patients of 75 years or older with advanced non-small cell lung cancer.}, author={Noriyuki Ebi and Hiroshi Semba and Sho J I Tokunaga and Koichi Takayama and Hiroshi Wataya and Takashige Kuraki and Hidehiko Yamamoto and Shin J I Akamine and Isamu Okamoto and Yoichi Nakanishi}, journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer}, year={2008}, volume={3 10}, pages={1166-71} }